Fig. 1From: Pretreatment 18F‐FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancerDistribution of metastases per patient and HI50% of all metastases in individual patientsBack to article page